Rein Therapeutics (RNTX) Operating Expenses (2016 - 2026)
Rein Therapeutics (RNTX) posted quarterly Operating Expenses of $5.2 million for Q1 2026, down 6.76% year-over-year from $5.6 million in Q1 2025, and down 83.99% quarter-over-quarter from $32.7 million in Q4 2025.
Rein Therapeutics (RNTX) Operating Expenses (2016 - 2026) Analysis & Trends
Rein Therapeutics (RNTX) has reported Operating Expenses for 11 consecutive years, with $5.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Expenses fell 6.76% year-over-year to $5.2 million; the TTM figure through Mar 2026 stood at $50.3 million (down 20.88% YoY), while the FY2025 annual figure was $50.6 million, down 22.24% from the prior year.
- Operating Expenses declined to $5.2 million in Q1 2026 per RNTX's latest filing, from $32.7 million in the prior quarter.
- Across five years, Operating Expenses topped out at $42.8 million in Q4 2024 and bottomed at $2.0 million in Q3 2023.
- Historically, Operating Expenses has averaged $9.7 million across 5 years, with a median of $6.5 million in 2022.
- Annual changes were most pronounced in 2023 — Operating Expenses slumped 75.23% — and 2024, when it surged 487.06%.
- Rein Therapeutics' Operating Expenses stood at $4.7 million in 2022, then surged by 55.01% to $7.3 million in 2023, then soared by 487.06% to $42.8 million in 2024, then dropped by 23.69% to $32.7 million in 2025, then tumbled by 83.99% to $5.2 million in 2026.
- Business Quant data shows RNTX's Operating Expenses at $5.2 million in Q1 2026, $32.7 million in Q4 2025, and $5.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.94 Bn | 132.09 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 86.59 Bn | 78.60 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 65.67 Bn | 60.49 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 57.81 Bn | 52.67 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 42.25 Bn | 37.15 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 31.76 Bn | 28.45 Bn | 992.69 Mn | 1.06 Bn |
| 7 | BioNTech SE | 28.41 Bn | 10.02 Bn | 668.28 Mn | -784.57 Mn |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | 427.03 Mn |
| 9 | Royalty Pharma | 27.24 Bn | 26.41 Bn | - | 541.02 Mn |
| 10 | Rein Therapeutics | 54.89 Mn | 54.89 Mn | - | 6.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.08 Mn |
| Mar 31, 2026 | 5.23 Mn |
| Dec 31, 2025 | 32.66 Mn |
| Sep 30, 2025 | 5.49 Mn |
| Jun 30, 2025 | 6.87 Mn |
| Mar 31, 2025 | 5.61 Mn |
| Dec 31, 2024 | 42.80 Mn |
| Sep 30, 2024 | 6.07 Mn |
| Jun 30, 2024 | 9.04 Mn |
| Mar 31, 2024 | 7.21 Mn |
| Dec 31, 2023 | 7.29 Mn |
| Sep 30, 2023 | 1.98 Mn |
| Jun 30, 2023 | 1.99 Mn |
| Mar 31, 2023 | 5.01 Mn |
| Dec 31, 2022 | 4.70 Mn |
| Sep 30, 2022 | 6.48 Mn |
| Jun 30, 2022 | 8.04 Mn |
| Mar 31, 2022 | 8.42 Mn |
| Dec 31, 2021 | 6.82 Mn |
| Sep 30, 2021 | 6.79 Mn |